CI-1040

DB12429InvestigationalSmall molecule

CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₁₇H₁₄ClF₂IN₂O₂ · 478.66 g/mol (avg)
Code names: CI-1040 · PD-184352

Resolves to

Compound

UNIIR3K9Y00J04CAS212631-79-3ChEMBLCHEMBL105442ChEBI91353PubChem6918454

Structure

InChIKeyGFMMXOIFOQCCGU-UHFFFAOYSA-NSMILESFC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1

Targets

Q02750MAP2K1P36507MAP2K2P31749AKT1P49841GSK3BP53778MAPK12O14757CHEK1P06239LCKQ16539MAPK14+9 more

What you can answer from here — as of June 15, 2026

17Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

47+ReferencesStructured and connected to the statements they support

Which drugs share a target with CI-1040, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account